Skip to main content
Clinical Trials/NCT01886690
NCT01886690
Completed
Phase 3

A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery

Allergan0 sites148 target enrollmentAugust 20, 2013

Overview

Phase
Phase 3
Intervention
carboxymethylcellulose sodium based new eye drop formulation
Conditions
Bilateral LASIK Surgery
Sponsor
Allergan
Enrollment
148
Primary Endpoint
Ocular Surface Disease Index© (OSDI) Score Using a 5-Point Scale
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study will compare the safety and efficacy of a new eye drop formulation with REFRESH PLUS® in participants following LASIK surgery.

Registry
clinicaltrials.gov
Start Date
August 20, 2013
End Date
August 18, 2014
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Allergan
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for LASIK surgery in both eyes.

Exclusion Criteria

  • Any systemic medication use within 3 months of screening (including over the counter, herbal, prescription, or nutritional supplement) which may affect dry eye or vision
  • Use of topical eye medication other than prescribed for use in pre- or post-operative care
  • Use of RESTASIS® or other topical ophthalmic cyclosporine product within 6 months prior to Screening
  • Eye infection, inflammation, or allergy
  • Soft contact lenses in the previous 7 days or rigid contact lenses in the previous 30 days prior to LASIK surgery.

Arms & Interventions

New Eye Drop Formulation

1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.

Intervention: carboxymethylcellulose sodium based new eye drop formulation

REFRESH PLUS®

1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.

Intervention: carboxymethylcellulose sodium based eye drops

Outcomes

Primary Outcomes

Ocular Surface Disease Index© (OSDI) Score Using a 5-Point Scale

Time Frame: Day 90

The OSDI© is a 12-question survey for patients to document their dry eye disease symptoms. Each question is rated on a 5-point scale (0=none of the time and 4 = all of the time). The scores are totaled over the 12 questions and normalized/converted to a score of 0-100 (0=no disability and 100=complete disability).

Secondary Outcomes

  • Change From Baseline in Corneal Staining in the Worse Eye(Baseline, Day 90)
  • Change From Baseline in Tear Break-up Time (TBUT) in the Worse Eye(Baseline, Day 90)
  • Change From Baseline in the Schirmer Test in the Worse Eye(Baseline, Day 90)
  • Change From Baseline in Uncorrected Visual Acuity in the Worse Eye(Baseline, Day 90)

Similar Trials